首页> British journal of haematology> Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.

Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.

导出 LinkOut

翻译打印收藏纠错

第一作者： Filippo,Spriano

第一单位： Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

作者： Filippo,Spriano ^[1] ; Chiara,Tarantelli ^[1] ; Luciano,Cascione ^[2] ; Eugenio,Gaudio ^[1] ; Gaetanina,Golino ^[1] ; Lorenzo,Scalise ^[1] ; Maria Teresa,Cacciapuoti ^[3] ; Emanuele,Zucca ^[4] ; Anastasios,Stathis ^[5] ; Patrick H,Van Berkel ^[6] ; Giorgio,Inghirami ^[3] ; Francesca,Zammarchi ^[6] ; Francesco,Bertoni ^[4]

作者单位： Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland. ^[1] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.;SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. ^[2] Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA. ^[3] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.;Department of Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland. ^[4] Department of Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.;Faculty of Biomedical Sciences, USI, Lugano, Switzerland. ^[5] ADC Therapeutics (UK) Ltd., London, UK. ^[6]

关键词 CD25 T‐cell lymphoma antibody‐drug conjugate camidanlumab tesirine lymphomas